Phenotypes associated with this allele

• Allele Symbol: Tnfrsf11a^tm1Kost
• Allele Name: targeted mutation 1, Paul J Kostenuik
• Allele ID: MGI:4840355
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Tnfrsf11a^tm1Kost/Tnfrsf11a^tm1Kost	involves: 129/Sv * Black Swiss	MGI:4840372

Genotype
MGI:4840372

hm1

• Allelic Composition: Tnfrsf11a^tm1Kost/Tnfrsf11a^tm1Kost
• Genetic Background: involves: 129/Sv * Black Swiss

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

growth/size/body

decreased body weight ( J:166279 )

• slightly lower body weight than controls at 13-16 weeks of age

• body weight is similar to controls at 10 months of age

limbs/digits/tail

increased femoral compact bone area ( J:166279 )

• greater cortical bone area in the midshaft of the femur

skeleton

abnormal bone structure ( J:166279 )

abnormal osteoclast morphology ( J:166279 )

• significantly reduced osteoclast surface relative to controls at 8-12 weeks of age

• reduced osteoclast surface after Denosumab treatment of 10 month old mice

increased femoral compact bone area ( J:166279 )

• greater cortical bone area in the midshaft of the femur

increased bone mineral density ( J:166279 )

• after Denosumab treatment of 10 month old mice

increased bone volume ( J:166279 )

• 2 fold increase in bone volume/total volume ratio

increased trabecular bone volume ( J:166279 )

• greater trabecular bone volume after Denosumab treatment of 10 month old mice

abnormal osteoblast morphology ( J:166279 )

• significantly reduced osteoblast surface relative to controls at 8-12 weeks of age

• osteoblast surface at the proximal tibial metaphysis is not reduced

• lower osteoblast surface after Denosumab treatment of 10 month old mice

increased bone trabecula number ( J:166279 )

• increased trabecular number in the distal metaphysis of the femur

increased trabecular bone thickness ( J:166279 )

• after Denosumab treatment of 10 month old mice

abnormal skeleton physiology ( J:166279 )

abnormal bone mineralization ( J:166279 )

• reduced trabecular mineralizing surface after Denosumab treatment of 10 month old mice

• reduced mineral apposition rate

• reduced bone formation rate

abnormal bone remodeling ( J:166279 )

• treatment with Denosumab, a monoclonal antibody against human RANKL results in a more than 95% reduction in osteoclast surface/bone surface ratio

hematopoietic system

abnormal osteoclast morphology ( J:166279 )

• significantly reduced osteoclast surface relative to controls at 8-12 weeks of age

• reduced osteoclast surface after Denosumab treatment of 10 month old mice

immune system

abnormal osteoclast morphology ( J:166279 )

• significantly reduced osteoclast surface relative to controls at 8-12 weeks of age

• reduced osteoclast surface after Denosumab treatment of 10 month old mice